Novo Nordisk’s High-Dose Wegovy Demonstrates Superior Weight Loss of 20.7% in Phase IIIb Trial

Weight Loss Percentage:
High-dose Wegovy (semaglutide 7.2 mg) resulted in a 20.7% weight loss over 72 weeks in obese adults, significantly higher than the standard dose (2.4 mg) and placebo12.

Trial Design:
The STEP UP trial was a 72-week efficacy and safety trial involving 1,407 adults with obesity, comparing semaglutide 7.2 mg to semaglutide 2.4 mg and placebo, all administered once weekly with lifestyle interventions2.

Safety Profile:
The 7.2 mg dose was reported to have a safe and well-tolerated profile, with gastrointestinal adverse events being mild to moderate and diminishing over time2.

Significant Outcomes:
33.2% of subjects receiving the higher dose achieved 25% or more weight loss, compared to 16.7% with the standard dose and 0.0% with placebo12.

Future Expectations:
Results from the STEP UP T2D trial, evaluating semaglutide 7.2 mg in adults with type 2 diabetes and obesity, are expected in the following months12.

Sources:

1. https://www.clinicaltrialsarena.com/news/novo-nordisk-trial-semaglutide/

2. https://www.globenewswire.com/news-release/2025/01/17/3011376/0/en/Novo-Nordisk-A-S-Semaglutide-7-2-mg-s-c-achieved-20-7-weight-loss-in-the-STEP-UP-obesity-trial-and-18-7-regardless-of-treatment-adherence.html